Who's speaking at this Webinar?
Max Crispin, D. Phil.
Professor of Glycobiology University of Southampton, UK
Researcher, Unviersity of Southampton, UK
Marshall Bern, Ph.D.
VP of Research and Co-Founder, Protein Metrics Inc
Scientists worldwide are working tirelessly to develop a vaccine for SARS-CoV-2 (the COVID-19 betacoronovirus), focusing on the humoral immune response to the spike (S) glycoprotein. Understanding the S protein’s glycosylation can reveal fundamental features of viral biology for use in the development and manufacturing of serological testing kits and potential vaccines.
In this webinar, Max Crispin and Joel Allen will share how they characterized both the site-specific N-linked glycan composition and the degree of sequon occupancy on a soluble, native-like SARS-CoV-2 S protein. The sequon occupancy likely plays a role in immune evasion and occlusion of immunogenic proteins.
Marshall Bern of Protein Metrics will also share how Protein Metrics’ advanced analytical software contributes detailed benchmarking of virus glycosylation.
Attendees can expect to learn how to:
- Conduct detailed site-specific glycosylation analysis using mass spectrometry and advanced protein characterization software
- Rapidly compare different immunogens and target strategies for detection and vaccine development
- Map glycan processing states and show how SARS-CoV-2 glycan processing differs from that of typical host glycans
- Analyze oligomannose and hybrid-type glycan quantities